Royalty Pharma plc - Ordinary Shares - Class A Stock News

As we enter the tail end of 2024, which has been a great year for the markets, as the S&P 500 has rallied by 27.35% since the beginning of the year, one question lies on the minds of investors the world over — what do I invest in for next year?

The benchmark S&P 500 index keeps reaching new highs, but not all of its components have participated in the rally. Royalty Pharma (RPRX 0.04%), W.P.

The benchmark stock indexes keep climbing to new heights, but there are plenty of attractive wallflowers at this dance. A couple of overlooked dividend payers offer high yields and reliable dividend payout growth, but you wouldn't know it by looking at their stock prices.

It's been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the benchmark S&P 500 (^GSPC 0.24%) index rose a whopping 57.1% higher.

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December:

The 'Undercovered' Dozen series highlights 12 lesser-covered stocks from the past week, aiming to spark ideas and discussions among retail investors. Veradigm Inc. is undervalued due to regulatory pressures, but has significant upside potential with strategic buyers potentially paying mid- or high-teens per share. Casey's General Stores has outperformed its peers and the S&P 500 due to its stra...

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or organizations who positively impact healthcare, was awarded to Micheal Milken. The prize includes a $250,000 charitable donation to support medical research or educational initiatives that further the recipient's w...

3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade